Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence

SARS-CoV-2 infection causes COVID-19, which frequently leads to clinical deterioration and/or long-lasting morbidity. Academic and governmental experts throughout the USA met in 2021 to discuss the potential for use of fluvoxamine as early treatment of SARS-CoV-2 infection. Fluvoxamine is a selectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Facente, Shelley N., Reiersen, Angela M., Lenze, Eric J., Boulware, David R., Klausner, Jeffrey D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633915/
https://www.ncbi.nlm.nih.gov/pubmed/34851510
http://dx.doi.org/10.1007/s40265-021-01636-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633915/
https://www.ncbi.nlm.nih.gov/pubmed/34851510
http://dx.doi.org/10.1007/s40265-021-01636-5

Ejemplares similares